Srinivasan Beddhu
No Rating Available
(Learn About Our Rating System)

Srinivasan Beddhu, MD

Languages spoken: English, Tamil

Clinical Locations

Primary Location

Veterans Administration Medical Center

500 S Foothill Blvd
Salt Lake City , UT 84148
Get Directions

  • Dr. Beddhu is a Professor and Dialysis Research Foundation Presidential Endowed Chair in the Department of Internal Medicine. He also serves as the Clinical Research Medical Director in the Department of Internal Medicine. His research focus is on cardiovascular disease, nutritional status and lifestyle factors in CKD and dialysis patients. He leads a strong research team that is conducting studies of large national databases using cutting-edge statistical techniques and investigator initiated randomized controlled trials.

    His research is funded by NIH, VA and industry with his current total federal funding exceeding $10 million. He was actively involved for 9 years in the NHLBI-funded Systolic Blood Pressure Intervention Trial (SPRINT) as the Co-Director of the Utah Clinical Center Network (CCN) and the Utah site- PI. He has authored more than 150 publications with many papers in high impact journals. He has mentored junior faculty, post-docs, fellows, residents, graduate students and medical students, some of whom have become independent, funded investigators.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine

  • Dr. Beddhu is a Professor and Dialysis Research Foundation Presidential Endowed Chair in the Department of Internal Medicine. He also serves as the Clinical Research Medical Director in the Department of Internal Medicine. His research focus is on cardiovascular disease, nutritional status and lifestyle factors in CKD and dialysis patients. He leads a strong research team that is conducting studies of large national databases using cutting-edge statistical techniques and investigator initiated randomized controlled trials.

    His research is funded by NIH, VA and industry with his current total federal funding exceeding $10 million. He was actively involved for 9 years in the NHLBI-funded Systolic Blood Pressure Intervention Trial (SPRINT) as the Co-Director of the Utah Clinical Center Network (CCN) and the Utah site- PI. He has authored more than 150 publications with many papers in high impact journals. He has mentored junior faculty, post-docs, fellows, residents, graduate students and medical students, some of whom have become independent, funded investigators.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Population Health Sciences -Adjunct Professor
    Academic Divisions Nephrology & Hypertension
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine

    Education history

    Research Fellow Renal Division - University of Pittsburg Research Fellow
    Fellowship Nephrology - University Health Center of Pittsburgh Fellow
    Residency Internal Medicine - St. Mary's Hospital of Rochester Resident
    Residency Internal Medicine - Bangalore Medical College Resident
    Residency Internal Medicine - Stanley Medical College Resident
    Professional Medical Medicine - Stanley Medical College M.B.B.S.
    Undergraduate D. B. Higher SEC - School

    Selected Publications

    Journal Article

    1. Sarwal A, Singh R, Wei G, Shen J, Nevers M, Hartsell SE, Derington CG, Takyi A, Chakravartula AR, Katkam N, Boucher RE, Drakos SG, Greene T, Beddhu S (2025). Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes. Diabetes Obes Metab. (Read full publication)
    2. Zhou J, Williams C, Staplin N, Judge PK, Mayne KJ, Agrawal N, Arimoto R, Green JB, Cherney DZI, Tuttle KR, Leal J, Clarke P, Emberson JR, Preiss D, Wanner C, Landray MJ, Baigent C, Haynes R, Herrington WG, Mihaylova B, EMPA-KIDNEY Collaborative Group (2025). Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial. EClinicalMedicine, 85, 103338. (Read full publication)
    3. Brinker L, Sideris K, Wei G, Singh R, Nevers MR, Hartsell SE, Sarwal A, Kyriakopoulos CP, Tseliou E, Benes J, Melenovsky V, Drakos SG, Hanff TC, Carter S, Fang JC, Cho M, Beddhu S, Stehlik J (2025). Diabetes Therapy With SGLT2i After Heart Transplant: A Multi-Institutional Analysis. JACC Heart Fail, 13(8), 102520. (Read full publication)
    4. Rossing P, Birkenfeld AL, Fioretto P, McGill JB, Anker SD, Pitt B, Rohwedder K, Scalise A, Scott C, Filippatos G, FIDELIO-DKD and FIGARO-DKD Investigators (2025). Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis. Clin J Am Soc Nephrol, 20(7), 968-977. (Read full publication)
    5. Sarwal A, Boucher RE, Hartsell SE, Wei G, Shen J, Chertow GM, Whelton PK, Cheung AK, McEvoy JW, Greene T, Beddhu S (2024). Baseline Diastolic BP and BP-Lowering Effects on Cardiovascular Outcomes and All-Cause Mortality: A Meta-Analysis. J Am Soc Nephrol, 36(5), 911-922. (Read full publication)
    6. Beddhu S, Shiu YT (2025). Muscle Wasting and Arteriovenous Fistula Nonmaturation in Kidney Failure. J Am Soc Nephrol, 36(5), 758-759. (Read full publication)
    7. Shen J, Sarwal A, Singh R, Hartsell SE, Wei G, Nevers M, Christensen JC, Takyi A, Katkam N, Derington CG, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Beddhu S (2025). Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes. Diabetes Obes Metab, 27(4), 2120-2130. (Read full publication)
    8. EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R, EMPA-KIDNEY Collaborative Group (2024). Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 392(8), 777-787. (Read full publication)
    9. Christensen JC, Anand S, Chertow GM, Lyden K, Sarwal A, Bjordahl T, Boucher R, Mohammed A, Oro EG, Akramimoghaddam F, Katkam N, Takyi A, Bissada G, Chakravartula AR, Lee E, Zheng A, Wei G, Greene T, Beddhu S (2024). The Sit Less, Interact and Move More (SLIMM-2) Trial: Protocol for a randomized control trial of a sedentary behavior intervention, resistance training and semaglutide on sedentary behavior in persons with chronic kidney disease. Contemp Clin Trials, 149, 107766. (Read full publication)
    10. Pajewski NM, Beddhu S, Bress AP, Chang TI, Chertow GM, Cheung AK, Cushman WC, Freedman BI, Greene T, Johnson KC, Jaeger BC, Tamura MK, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Williamson JD, Whelton PK, Wright JT Jr, Drawz PE, Ix JH (2024). The Legacy Effect of Intensive versus Standard BP Control on the Incidence of Needing Dialysis or Kidney Transplantation. J Am Soc Nephrol, 35(12), 1737-1745. (Read full publication)
    11. Ikizler TA, Kramer HJ, Beddhu S, Chang AR, Friedman AN, Harhay MN, Jimenez EY, Kistler B, Kukla A, Larson K, Lavenburg LU, Navaneethan SD, Ortiz J, Pereira RI, Sarwer DB, Schauer PR, Zeitler EM, ASN Kidney Health Guidance Workgroup on Obesity and Kidney Diseases (2024). ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases. J Am Soc Nephrol, 35(11), 1574-1588. (Read full publication)
    12. Akbari S, Ten Eyck P, Wendt L, Yamada M, Boucher R, Beddhu S, Jalal DI (2024). Trends of Blood Pressure Control in Chronic Kidney Disease Among US Adults: Findings From NHANES 2011 to 2020. J Am Heart Assoc, 13(20), e034568. (Read full publication)
    13. Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Cheung AK, Maggioni AP, Nangaku M, Rossello X, Tuttle KR, Ihara K, Iwata T, Wanner C, Emberson J, Preiss D, Landray MJ, Baigent C, Haynes R, Herrington WG, EMPA-KIDNEY Collaborative Group (2024). Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial. Clin J Am Soc Nephrol, 19(9), 1119-1129. (Read full publication)
    14. Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL, FIDELIO-DKD and FIGARO-DKD Investigators (2023). Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med, 176(12), 1606-1616. (Read full publication)
    15. Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, Tuttle KR, Ruilope LM, Rossing P, Toto R, Anker SD, Liu ZH, Joseph A, Ahlers C, Brinker M, Lawatscheck R, Bakris G, FIDELIO-DKD and FIGARO-DKD Investigators (2023). Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol, 18(5), 602-612. (Read full publication)
    16. Gupta A, Boucher R, Wei G, Gronseth G, Parks A, Beddhu S (2022). Influence of Baseline Diastolic Blood Pressure on the Effects of Systolic Blood Pressure Lowering on Cognitive Function in Type 2 Diabetes Mellitus. Am J Hypertens, 36(2), 120-125. (Read full publication)
    17. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2022). Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 388(2), 117-127. (Read full publication)
    18. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R, FIDELIO-DKD and FIGARO-DKD Investigators (2022). Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care, 45(12), 2991-2998. (Read full publication)
    19. Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM (2022). Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. Obesity (Silver Spring), 30(12), 2340-2350. (Read full publication)
    20. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL, FIDELIO-DKD Investigators (2021). Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care, 45(4), 888-897. (Read full publication)
    21. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM, FIGARO-DKD Investigators (2021). Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med, 385(24), 2252-2263. (Read full publication)
    22. SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius WT (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 384(20), 1921-1930. (Read full publication)
    23. SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius WT (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 384(20), 1921-1930. (Read full publication)
    24. Lyden K, Boucher R, Wei G, Zhou N, Christensen J, Chertow GM, Greene T, Beddhu S (2021). Targeting Sedentary Behavior in CKD: A Pilot and Feasibility Randomized Controlled Trial. Clin J Am Soc Nephrol, 16(5), 717-726. (Read full publication)
    25. Nasrallah IM, Gaussoin SA, Pomponio R, Dolui S, Erus G, Wright CB, Launer LJ, Detre JA, Wolk DA, Davatzikos C, Williamson JD, Pajewski NM, Bryan RN, SPRINT Research Group (2021). Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial. JAMA Neurol, 78(5), 568-577. (Read full publication)
    26. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G, FIDELIO-DKD Investigators (2020). Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med, 383(23), 2219-2229. (Read full publication)
    27. Chang AR, Kramer H, Wei G, Boucher R, Grams ME, Berlowitz D, Bhatt U, Cohen DL, Drawz P, Punzi H, Freedman BI, Haley W, Hawfield A, Horwitz E, McLouth C, Morisky D, Papademetriou V, Rocco MV, Wall B, Weiner DE, Zias A, Beddhu S, SPRINT Research Group (2020). Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria: Post Hoc Analyses from SPRINT. Clin J Am Soc Nephrol, 15(8), 1121-1128. (Read full publication)
    28. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, Ambrosius W, Chertow GM, Beddhu S (2020). The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. Diabetes Care, 43(8), 1878-1884. (Read full publication)
    29. Chang TI, Wei G, Boucher R, Kramer H, Chertow GM, Cheung AK, Greene T, Whelton PK, Beddhu S (2020). Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease. Kidney360, 1(5), 368-375. (Read full publication)
    30. Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, Beddhu S (2020). Sodium Bicarbonate Supplementation and Urinary TGF-β1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial. Clin J Am Soc Nephrol, 15(2), 200-208. (Read full publication)
    31. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene T (2019). Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. J Am Soc Nephrol, 30(8), 1523-1533. (Read full publication)
    32. Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D, SONAR Committees and Investigators (2019). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, 393(10184), 1937-1947. (Read full publication)
    33. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G, onbehalfoftheFIDELIO-DKDstudyinvestigators, FIDELIO-DKDstudyinvestigators (2019). Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol, 50(5), 333-344. (Read full publication)
    34. Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B, FIGARO-DKDstudyinvestigators (2019). Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol, 50(5), 345-356. (Read full publication)
    35. Beddhu S, Chertow GM, Greene T, Whelton PK, Ambrosius WT, Cheung AK, Cutler J, Fine L, Boucher R, Wei G, Zhang C, Kramer H, Bress AP, Kimmel PL, Oparil S, Lewis CE, Rahman M, Cushman WC (2018). Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. J Am Heart Assoc, 7(18), e009326. (Read full publication)
    36. Tian M, Tang L, Wu Y, Beddhu S, Huang Y (2018). Adiponectin attenuates kidney injury and fibrosis in deoxycorticosterone acetate-salt and angiotensin II-induced CKD mice. Am J Physiol Renal Physiol, 315(3), F558-F571. (Read full publication)
    37. Beddhu S, Greene T, Boucher R, Cushman WC, Wei G, Stoddard G, Ix JH, Chonchol M, Kramer H, Cheung AK, Kimmel PL, Whelton PK, Chertow GM (2018). Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol, 6(7), 555-563. (Read full publication)
    38. Johnson KC, Whelton PK, Cushman WC, Cutler JA, Evans GW, Snyder JK, Ambrosius WT, Beddhu S, Cheung AK, Fine LJ, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Oparil S, Wright JT Jr, SPRINT Research Group (2018). Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 71(5), 848-857. (Read full publication)
    39. Kramer H, Boucher RE, Leehey D, Fried L, Wei G, Greene T, Rosas SE, Cooper R, Cao G, Beddhu S (02/07/2018). Increasing Mortality in Adults With Diabetes and Low Estimated Glomerular Filtration Rate in the Absence of Albuminuria. Diabetes Care, 41(4), 775-781.
    40. Beddhu S, Chertow GM, Cheung AK, Cushman WC, Rahman M, Greene T, Wei G, Campbell RC, Conroy M, Freedman BI, Haley W, Horwitz E, Kitzman D, Lash J, Papademetriou V, Pisoni R, Riessen E, Rosendorff C, Watnick SG, Whittle J, Whelton PK, SPRINT Research Group (01/09/2018). Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. Circulation, 137(2), 134-143.
    41. Beddhu S, Rocco M, Toto R, Craven TE, Greene T, Bhatt U, Cheung AK, Cohen D, Freedman BI, Hawfield AT, Kileen AA, Kimmell PL, LashJ, Papademtriou V, Rahman M, Rastogi A, Servilla K, Townsend RR, Wall B, Whelton PK, SPRINT Rsearch Group (09/19/2017). Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Withour Kidney Disease: A Secondary Analysis of Randomized Trial. Ann Intern Med, 167(6), 375-383.
    42. Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J, SPRINT Research Group (2017). Effects of Intensive BP Control in CKD. J Am Soc Nephrol, 28(9), 2812-2823. (Read full publication)
    43. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negrn N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS, Moran AE, SPRINT Research Group (08/24/2017). Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 377(8), 745-755.
    44. Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V, SPRINT Research Group (2017). Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care, 40(10), 1401-8. (Read full publication)
    45. Raphael KL, Carroll DJ, Murray J, Greene T, Beddhu S (08/01/2017). Urine Ammonium Predicts Clinical Outcomes in Hypertensive Kidney Disease. J Am Soc Nephrol, 28(8), 2483-2490.
    46. Velasquez MT, Beddhu S, Nobakht E, Rahman M, Raj DS (2016). Ambulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time? Kidney Int Rep, 1(2), 94-104. (Read full publication)
    47. Chen X, Wei G, Jalili T, Metos J, Giri A, Cho ME, Boucher R, Greene T, Beddhu S (2016). The Associations of Plant Protein Intake With All-Cause Mortality in CKD. Am J Kidney Dis, 67(3), 423-30.
    48. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 373(22), 2103-16. (Read full publication)
    49. Beddhu S, Wei G, Marcus RL, Chonchol M, Greene T (2015). Light-intensity physical activities and mortality in the United States general population and CKD subpopulation. Clin J Am Soc Nephrol, 10(7), 1145-53.
    50. Krishnamurthy VM, Wei G, Baird BC, Murtaugh M, Chonchol MB, Raphael KL, Greene T, Beddhu S (2012). High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int, 81(3), 300-6. (Read full publication)
    51. Raphael KL, Wei G, Baird BC, Greene T, Beddhu S (2011). Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int, 79(3), 356-62. (Read full publication)
    52. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S (2011). Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney Int, 79(2), 228-33. (Read full publication)
    53. Beddhu S, Baird BC, Zitterkoph J, Neilson J, Greene T (2009). Physical activity and mortality in chronic kidney disease (NHANES III). Clin J Am Soc Nephrol, 4(12), 1901-6. (Read full publication)
    54. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S (2009). Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol, 4(10), 1565-74. (Read full publication)
    55. Kwan BC, Murtaugh MA, Beddhu S (2007). Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. Clin J Am Soc Nephrol, 2(5), 992-8. (Read full publication)
    56. Beddhu S, Kimmel PL, Ramkumar N, Cheung AK (2005). Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis, 46(4), 577-86. (Read full publication)
    57. Morris D, Samore MH, Pappas LM, Ramkumar N, Beddhu S (2005). Nutrition and racial differences in cardiovascular events and survival in elderly dialysis patients. Am J Med, 118(6), 671-5. (Read full publication)
    58. Beddhu S, Pappas LM, Ramkumar N, Samore MH (2004). Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol, 15(3), 733-42. (Read full publication)
    59. Beddhu S, Pappas LM, Ramkumar N, Samore M (2003). Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol, 14(9), 2366-72. (Read full publication)
    60. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Ramkumar N, Pappas LM, Cheung AK (2003). Impact of timing of initiation of dialysis on mortality. J Am Soc Nephrol, 14(9), 2305-12. (Read full publication)
    61. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK (2003). Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol, 14(4), 1000-5. (Read full publication)
    62. Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, Anderson JL (2002). Impact of renal failure on the risk of myocardial infarction and death. Kidney Int, 62(5), 1776-83. (Read full publication)
    63. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML (2000). A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med, 108(8), 609-13. (Read full publication)

    Review

    1. Kramer HJ, Townsend RR, Griffin K, Flynn JT, Weiner DE, Rocco MV, Choi MJ, Weir MR, Chang TI, Agarwal R, Beddhu S (2018). KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. [Review]. Am J Kidney Dis, 73(4), 437-458. (Read full publication)
    2. Kramer H, Tuttle KR, Leehey D, Luke A, Durazo-Arvizu R, Shoham D, Cooper R, Beddhu S (2009). Obesity management in adults with CKD. [Review]. Am J Kidney Dis, 53(1), 151-65. (Read full publication)

    Editorial

    1. Anand S, Beddhu S (2025). BPROAD - End of the Road for Debate on Systolic Blood-Pressure Goals in Type 2 Diabetes? N Engl J Med, 392(12), 1230-1232. (Read full publication)
    2. Katkam N, Beddhu S (2024). Steps for Stopping Kidney Stones: Physical Activity Triumphant Over Genetics. Am J Kidney Dis, 84(4), 403-405. (Read full publication)
    3. Mohan A, Beddhu S (2024). Invisible Threat: How Air Pollution Fuels Primary Glomerular Disease. Kidney Int Rep, 9(9), 2591-2593. (Read full publication)
    4. Koppe L, Beddhu S, Chauveau P, Kovesdy CP, Mafra D, Joshi S, Kalantar-Zadeh K, Fouque D (2021). A call for a better understanding of the role of dietary amino acids and post-translational protein modifications of the microbiome in the progression of CKD. Nephrol Dial Transplant, 36(8), 1357-1360. (Read full publication)

    Letter

    1. Beddhu S, Greene T, Boucher R, Cushman WC, Wei G, Cheung AK, Whelton PK, Chertow GM (2018). Risk-benefit profile of intensive blood pressure treatment - Authors' reply. [Letter to the editor]. Lancet Diabetes Endocrinol, 6(8), 602. (Read full publication)

    Other

    1. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL, FIDELIO-DKD Investigators (2023). Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897. Diabetes Care (46(9), p. 1721). United States. (Read full publication)

    Research Lab

  • News & Podcasts

    News